33406123|t|Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides.
33406123|a|We previously reported that IF7 peptide, which binds to the annexin A1 (ANXA1) N-terminus, functions as a tumor vasculature-targeted drug delivery vehicle after intravenous injection. To enhance IF7 stability in vivo, we undertook mirror-image peptide phage display using a synthetic D-peptide representing the ANXA1 N-terminus as target. We then identified peptide sequences, synthesized them as D-amino acids, and designated the resulting peptide dTIT7, which we showed bound to the ANXA1 N-terminus. Whole body imaging of mouse brain tumor models injected with near infrared fluorescent IRDye-conjugated dTIT7 showed fluorescent signals in brain and kidney. Furthermore, orally-administered dTIT7/geldanamycin (GA) conjugates suppressed brain tumor growth. Ours is a proof-of-concept experiment showing that ANXA1-binding D-peptide can be developed as an orally-administrable tumor vasculature-targeted therapeutic.
33406123	39	44	tumor	Disease	MESH:D009369
33406123	85	95	annexin A1	Gene	16952
33406123	104	105	D	Chemical	MESH:D003903
33406123	144	147	IF7	Gene	18356
33406123	176	186	annexin A1	Gene	16952
33406123	188	193	ANXA1	Gene	16952
33406123	222	227	tumor	Disease	MESH:D009369
33406123	311	314	IF7	Gene	18356
33406123	427	432	ANXA1	Gene	16952
33406123	513	515	D-	Chemical	MESH:D003903
33406123	601	606	ANXA1	Gene	16952
33406123	641	646	mouse	Species	10090
33406123	647	658	brain tumor	Disease	MESH:D001932
33406123	706	711	IRDye	Chemical	-
33406123	810	815	dTIT7	Chemical	-
33406123	816	828	geldanamycin	Chemical	MESH:C001277
33406123	830	832	GA	Chemical	-
33406123	856	867	brain tumor	Disease	MESH:D001932
33406123	927	932	ANXA1	Gene	16952
33406123	995	1000	tumor	Disease	MESH:D009369
33406123	Negative_Correlation	MESH:C001277	MESH:D001932
33406123	Association	MESH:D003903	16952
33406123	Association	MESH:D009369	16952
33406123	Association	16952	18356
33406123	Association	MESH:D009369	18356

